Annals of Oncology Advance Access originally published online on July 1, 2005
Annals of Oncology 2005 16(8):1217-1218; doi:10.1093/annonc/mdi298
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Editorial |
What is the impact of sentinel node biopsy in the management of cancer?
Centre Hospitalier Universitaire Vaudois and Ludwig Institute for Cancer Research, Lausanne, Switzerland
Email: ferdy.lejeune@chuv.hospvd.ch
| The first 10% of the full text of this article appears below. |
Sentinel node biopsy (SNB) is a surgical/histopathological diagnostic tool that is increasingly used but still being evaluated in surgical oncology.
The concept of sentinel node biopsy (SNB) was first established in melanoma of the skin [1
]. It is based on the observation that from a given area of the skin, lymphatic spreading of melanoma cells proceeds following sequential steps, in an orderly fashion. The first lymph node encountered by floating melanoma cells is called the sentinel node (SN) and SN is specifically (95%) the site of micrometastases if they exist. In case of unpalpable regional lymph node (N0), the histological status of